1789 TT

ScinoPharm Investor Conference

— 2026 08 17

ScinoPharm Taiwan

Copyright © 2026 ScinoPharm Co., Ltd. All rights reserved

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Overview of Business Operations

02 Business Update

03 Financial Performance



Overview of Business Operations

I. Operating Performance Under Pressure while Core Business Advances

- **Operating results**
  - Consolidated revenue of USD 42.3 million in 1H 2026, decrease of 6% yoy; 1,338 million in NTD, decrease of 7% yoy. NLAT: NTD 19 million
- **Business progress**
  - API Business: Sales and profits of some core APIs surpassed the same period last year, demonstrating the effectiveness of product pricing strategies and cost optimization
  - Pharma Business: Market expansion and product registration ongoing with non-U.S. market expansion proceeding as planned
  - CDMO Business: Short-term operating performance under pressure due to production adjustments; efforts to optimize production capacity allocation and business arrangements are ongoing factors affecting profitability
- **Factors affecting profitability**
  - Optimized product portfolio and cost refinement support gross profit performance
  - Some production schedule and supply adjustments impacting short-term operational progress; related operational optimization measures continuously being implemented. Operating deficits from subsidiaries also affecting profitability

Copyright © 2026 ScinoPharm Co., Ltd. . All rights reserved.

II. Leverage In-house Products' Advantages to Maximize Product and Market Value

API Business

- Enhance competitiveness and value creation capabilities of core products
- Optimize product portfolio and market deployment to expand high-value business opportunities
- Deepen understanding of market and customer needs to improve the accuracy of demand forecasting and order fulfillment
- Strengthen coordination amongst orders, production, and inventory to enhance resource allocation efficiency

Pharma Business

- Improve commercialization effectiveness of approved products to deepen market penetration
- Accelerate product approval and potential market expansion to drive growth momentum
- Optimize connection between market demands, product planning, and production plans to support product commercialization
- Deepen existing collaborations and expand strategic partnerships to expand portfolio of 505(b)(2) projects

Copyright © 2026 ScinoPharm Co., Ltd. . All rights reserved.

III. Expand CDMO Business Opportunities, Enhance Case Conversion and Delivery Value

- CDMO Business
  - Diversify customer bases to broaden business development channels
  - Integrate technology, business, and production capacity assessments to improve CDMO project conversion efficiency
  - Optimize project scheduling, capacity allocation, and personnel capabilities to improve CDMO project execution efficiency and supply flexibility
  - Deepen supply and demand collaboration and strengthen the reliability of production and delivery of critical orders
  - Strengthen customer relationships through stable delivery and professional services to enhance the value of long-term partnerships

Copyright © 2026 ScinoPharm Co., Ltd. . All rights reserved.



Business Update

Strengthening API Business

- Completed development of 77 proprietary API products and DMF filings, of which 37 products have supported finished drug products in commercial markets. Continue to closely monitor customers' registration as well as commercial launches
- Deepen understanding of market and customer needs, maintain stable supply and respond to price competition with flexible pricing strategies, secure existing market share and proactively follow up with new customers and new markets to maximize the value of our proprietary API business
- Expand the deployment of new product portfolio and pursue strategic partnerships with downstream formulation customers to secure supply opportunities and market share after commercial launch



Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.

Accelerating Pharma Business Development

- 21 drug products have been developed, of which 4 products have obtained approvals in US and TW, with 3 products under review
- Products for treating multiple sclerosis have been shipped to the US for market launch; products for treating multiple myeloma have been approved for inclusion in Taiwan's National Health Insurance reimbursement program, and preparations for product launch are underway
- Accelerate the approval of proprietary injectable products in US and TW and proactively expand non US market deployment

Data as of 2026/06/30

Therapeutic Areas	Project Numbers	Indication	Under Development	Technical Package Ready	Under Registration	Approved
Oncology	11	• Multiple Myeloma	1			1
		• Leukemia				1
		• Myelodysplastic Syndromes		1		
		• Oncology	1	6		
CNS	2	• Multiple Sclerosis				1
		• Reversal of Neuromuscular Blockade		1		
Cardiovascular	2	• Thromboembolic Disorders				1
		• Medical Imaging Agents		1		
Metabolism	6	• Osteoporosis			1	
		• Diabetes Mellitus	1	1	1	
		• Chronic Weight Management	1		1	

Note: The number mark in blue indicates the registration submission both in US and TW have been approved or are under review

Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.

Expanding CDMO Business

- Total of 62 CDMO active projects, 2 project that have reached the commercialized stage and 5 projects at R&D pre-clinical stage were added to API CDMO projects portfolio in 1H 2026
- By providing stable supply and professional technical services to gain customer trust and enhance the value of long-term collaboration
- Continuously enhance international exposure and customer reach, accumulate potential customers and strive for project proposals and successful projects, thereby maintaining the growth momentum of CDMO business

62 CDMO active projects

Data as of 2026/06/30



Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	1H 2026		YoY	1H 2025	
Revenue	1,338	100%	-7%	1,434	100%
Gross Profit	356	27%	-35%	548	38%
Operating Expenses	(413)	(31%)	-3%	(427)	(30%)
Operating Profit(Loss)	(57)	(4%)	-147%	120	8%
Net Profit(Loss) before Tax	(34)	(3%)	-133%	104	7%
Net Profit(Loss) after Tax	(19)	(1%)	-124%	80	6%
EPS (NTD)	(0.02)	-	-	0.10	-

Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.

Sales Distribution – By Business





Unit: USD/M

	API	Pharma	CDMO
1H 2026 Sales	33.5	1.8	7.0
YoY	-5.7%	NA	-28.2%

Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
1H 2026 Sales	25.6	11.3	5.4
YoY	-18.7%	36.7%	0.9%

Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.

Consolidated Balance Sheet

NTD Million	2026/06/30		2025/06/30	
Cash and Cash Equivalents	3,499	28%	3,086	26%
Accounts Receivable	347	3%	494	4%
Inventories	1,820	15%	1,896	16%
Property, Plant & Equipment	3,384	27%	3,490	29%
Financial Assets	1,574	13%	1,307	11%
Other Current/Non-Current Assets	1,736	14%	1,690	14%
Total Assets	**12,360**	**100%**	**11,963**	**100%**
Financial Debt	185	2%	83	1%
Other Current Liabilities	1,044	8%	977	8%
Other Non-Current Liabilities	670	5%	634	5%
Total Liabilities	**1,899**	**15%**	**1,694**	**14%**
Total Shareholders' Equities	**10,461**	**85%**	**10,269**	**86%**

Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.

Consolidated Cash Flow Statement

NTD million	1H 2026	1H 2025	Dif.
From Operating Activities	**437**	**227**	**210**
Depreciation & Amortization	257	254	3
From Investing Activities	**(101)**	**(1,323)**	**1,222**
Acquisition of financial assets	0	(1,156)	1,156
Capital Expenditure	(101)	(166)	65
From Financing Activities	**38**	**46**	**-8**
Effect of foreign exchange rate changes	15	(30)	45
Net Change in Cash	**389**	**(1,080)**	**1,469**
Beginning Balance	3,110	4,166	-1,056
Ending Balance	**3,499**	**3,086**	**413**

Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.



Q & A

Appendix
Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specialize in high-barrier APIs and drug products development and manufacturing, dedicated to providing fully integrated solutions as a trusted strategic partner for global clients. Core business includes APIs, drug Products and CDMO services
- Tainan API plant was certified by key international regulators – US FDA, Japanese PMDA, EMA, EDQM, Australian TGA, Korea KFDA, Mexico COFEPRIS, Brazilian ANVISA, German Authority and TFDA. Injectable plant was certified by US FDA and TFDA
- Changshu API plant was certified by US FDA and Japanese PMDA

Copyright © 2026 ScinoPharm Taiwan, Ltd. All rights reserved.

For every life. With every trust.

www.scinopharm.com

1789 TT